In our study, independently from the lymphoma type (i.e. HL or NHL), we observed a lack of association between the percentage of CD66b+CD33dimHLA-DR− cells or their subpopulations, and patient clinicopathological characteristics, including clinical stage, systemic symptoms, bone-marrow, spleen or extranodal involvement, and bulky disease. The gene discussed is CEACAM8; the disease is Hodgkins lymphoma.